Navigation Links
Promising new treatment option for women with recurrent ovarian cancer
Date:9/15/2008

Combining the new drug trabectedin with pegylated liposomal doxorubicin provides clinical benefit to women with relapsed ovarian cancer, according to new results presented at the 33rd Congress of the European Society for Medical Oncology (ESMO) in Stockholm.

The combination, which importantly does not include a platinum drug, challenges the current standard of treatment for women whose cancer recurs at least 6 months after first-line treatment, said Associate Prof. Bradley J. Monk from the University of California Irvine Medical Center.

"This trial, which included almost two-thirds such women, challenges this traditional paradigm and suggests that a non-platinum doublet is also effective in this setting," he said. "Trabectedin represents a 'new chemical entity' in North America and if approved by the FDA, would be an important new option for women with recurrent ovarian cancer."

Trabectedin, a synthetic version of a compound first isolated from sea-squirts, has been granted marketing approval in Europe for the treatment of patients with advanced soft tissue sarcoma.

In the latest trial, an international group of researchers studied the combination in 672 women whose ovarian cancer had progressed after first-line therapy. Half the women received pegylated liposomal doxorubicin 30 mg/m2 over 60 min plus trabectedin 1.1mg/m2 over 3 hours every 3 weeks, the remainder received pegylated liposomal doxorubicin 50 mg/m2 alone every 4 weeks.

The median length of progression-free survival for women on the combination therapy was 7.3 months, the researchers found, compared to 5.8 months for those treated with the single drug. For those who had relapsed more than six months after the first-line therapy, the median progression-free survival time was 9.2 months for the combination treatment, compared to 7.5 months for patients in the other arm.

"This drug appears active in all sub-groups included in the trial, but like all agents is most active among those with longer time intervals since their front-line chemotherapy treatment," Prof. Monk said.

"Positive trials in recurrent ovarian cancer are rare and have almost always led to newly approved therapeutic regimens," he said. "This combination will undoubtedly be carefully evaluated by the FDA and if approved would give women with ovarian cancer another much-needed option."


'/>"/>

Contact: ESMO Press Office
media@esmo.org
41-919-731-907
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. UIC researchers find promising new targets for antibiotics
2. New book defines promising young field of adult neurogenesis
3. Sirtris unveils promising, novel SIRT1 activators for treating diseases of aging
4. Cancer and arthritis therapy may be promising treatment for diabetes
5. Unique whey protein is promising supplement for strict PKU diet
6. Promising new drug targets identified for Huntingtons disease
7. Promising new nanotechnology for spinal cord injury
8. Biodesigns Rittmann offers promising perspectives on societys energy challenge
9. UIC researchers make promising finding in severe lung disease
10. New treatment approach promising for lymphoma patients in the developing world
11. Immunotherapy in high-risk pediatric sarcomas shows promising response
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... , May 16, 2017   Bridge ... health organizations, and MD EMR Systems , ... development partner for GE, have established a partnership ... Portal product and the GE Centricity™ products, including ... EMR. These new integrations will ...
(Date:4/24/2017)... April 24, 2017 Janice Kephart ... with  Identity Strategy Partners, LLP (IdSP) , today ... without President Trump,s March 6, 2017 Executive ... , refugee vetting can be instilled with greater confidence, ... now, all refugee applications are suspended by until ...
(Date:4/18/2017)... April 18, 2017  Socionext Inc., a global expert in SoC-based ... edge server, the M820, which features the company,s hybrid codec technology. ... by Tera Probe, Inc., will be showcased during the upcoming Medtec ... show at the Las Vegas Convention Center ... Click here ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... targeted antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it ... Nanoparticle), a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/10/2017)... ... October 10, 2017 , ... The Pittcon Program ... honoring scientists who have made outstanding contributions to analytical chemistry and ... 2018, the world’s leading conference and exposition for laboratory science, which will be ...
Breaking Biology Technology: